Merck's Welireg-Keytruda Combo Gets Priority FDA Review, June PDUFA Date
MRK sits 68% above its 52-week low of $73.31.
Summary
The FDA has set a PDUFA date of June 19, 2026, for Merck's Welireg and Keytruda combination therapy, granting it Priority Review for earlier-stage renal cell carcinoma. This follows positive clinical trial results showing the combination reduced the risk of disease recurrence or death by 28% compared to Keytruda monotherapy. This development adds to Merck's recent positive oncology news, including other promising Keytruda combinations and the Welireg-Lenvima therapy. A potential approval would significantly expand the market for Keytruda and Welireg, bolstering Merck's leading position in oncology. Traders will closely watch for the FDA's decision by the PDUFA date.
At the time of this announcement, MRK was trading at $123.31 on NYSE in the Life Sciences sector, with a market capitalization of approximately $306.1B. The 52-week trading range was $73.31 to $125.14. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.